This article defines Telemedicine as the use of electronic communication technologies (video conferencing, telephone, secure messaging, mobile applications) to provide clinical healthcare services when the patient and provider are separated by geographic distance. Digital health is a broader term encompassing telemedicine, wearable devices, health information technology, mobile health (mHealth), and artificial intelligence tools for health management. Core features: (1) synchronous (real-time) telehealth (live video consultations, virtual visits), (2) asynchronous (store-and-forward) telehealth (transmission of medical images, laboratory results, messages for later review), (3) remote patient monitoring (RPM) (collection and transmission of physiologic data – blood pressure, glucose, oxygen saturation, weight – from patient’s home), (4) mobile health (mHealth) (health-related applications, text message programmes, symptom checkers), (5) tele-education and tele-mentoring (virtual training, case discussions, specialist consultations for primary care providers). The article addresses: stated objectives of telemedicine; key concepts including virtual visit, reimbursement parity, digital divide, and tele-triage; core mechanisms such as platform selection, licensure and credentialing, privacy and security (HIPAA, GDPR compliance), and workflow integration; international comparisons and debated issues (quality and safety compared to in-person care, access disparities, regulatory barriers); summary and emerging trends (hospital-at-home with RPM, tele-ICU, AI triage chatbots); and a Q&A section.
This article describes telemedicine and digital health without endorsing specific platforms or vendors. Objectives commonly cited: expanding access to care for rural and underserved populations, reducing travel burden and wait times, lowering healthcare costs, enabling continuous monitoring of chronic conditions, and facilitating specialist consultations where local expertise is limited. The article notes that telemedicine utilisation increased dramatically during the period 2020-2022 (to levels up to 50-100 times pre-pandemic) and has remained at moderately elevated levels, though reimbursement and licensure barriers persist.
Key terminology:
Regulatory frameworks (selected countries):
Digital divide considerations: Access to broadband internet, suitable devices (computers, tablets, smartphones), digital literacy, and language/translation services affect telemedicine equity. Older adults, low-income individuals, rural residents, and individuals with limited English proficiency have lower telemedicine utilisation (20-40% lower) and higher rates of audio-only (telephone) use when video not available.
Telemedicine visit workflows:
Remote patient monitoring models:
Evidence base for telemedicine effectiveness:
Technology requirements:
Telemedicine adoption post-2020 (selected countries, 2024 estimates):
| Country/Region | % of primary care visits via telemedicine (2023) | Reimbursement parity (video vs in-person) | Cross-state/provider licensure barriers |
|---|---|---|---|
| United States | 15-25% (varies by state, specialty) | Partial (some states mandate priv rate equal for video) | Significant (state-based) |
| England (NHS) | 25-30% (including telephone, video) | NHS funded (free at point of care) | Single system (UK) |
| Australia | 15-20% | Medicare Benefits Schedule parity for selected items | Single system (Australia) |
| Canada | 10-20% (provincial variation) | Yes (provincial health insurance) | Inter-provincial barriers for virtual only |
Debated issues:
Summary: Telemedicine includes synchronous (video, telephone), asynchronous (store-and-forward), and remote patient monitoring. Evidence shows non-inferior outcomes for many ambulatory services (mental health, dermatology, chronic disease follow-up). Remote patient monitoring improves chronic condition control and reduces hospitalisations. Digital divide and licensure barriers limit equitable access.
Emerging trends:
Q1: Is telemedicine as effective as in-person care for all types of visits?
A: No. For routine follow-up of chronic conditions, medication management, mental health counselling, and dermatologic evaluation (by images), evidence supports non-inferiority. For initial evaluation of new, undifferentiated symptoms (especially chest pain, shortness of breath, abdominal pain, neurologic changes), in-person evaluation is generally recommended due to need for physical examination and testing.
Q2: What equipment is needed for a telemedicine visit at home?
A: Basic: smartphone, tablet, or computer with camera, microphone, and speaker; reliable internet connection (broadband or LTE/5G). For remote monitoring: blood pressure cuff, glucose meter, pulse oximeter, scale (may be provided by healthcare organisation). Peripheral attachments (digital stethoscope, otoscope) are rarely used at home.
Q3: How is privacy and security maintained during telemedicine visits?
A: HIPAA-compliant (US) or equivalent platforms use end-to-end encryption, secure login (two-factor authentication), access controls, and audit trails. Patients should conduct visits in private locations, and providers should use secure networks (not public Wi-Fi). Standard telehealth consent includes discussion of risks (interception, breach). Video recordings (if any) are stored in encrypted systems.
Q4: Can telemedicine reduce healthcare costs?
A: For patients, reduced travel time, lost wages, childcare costs. For systems, telemedicine substitutes lower-cost virtual visits for some higher-cost in-person visits. Remote monitoring reduces hospitalisations (20-30% for heart failure). However, telemedicine may increase total visits (convenience driving overuse). Net cost effect varies by context and condition.
https://www.who.int/health-topics/telehealth
https://www.americantelemed.org/
https://www.telehealth.hhs.gov/ (US)
https://www.england.nhs.uk/telehealth/
Related Articles
Jul 28, 2025 at 7:13 AM
May 13, 2026 at 8:08 AM
Feb 11, 2026 at 5:29 AM
Jul 3, 2025 at 3:38 AM
May 13, 2026 at 7:20 AM
Mar 9, 2026 at 7:10 AM
May 8, 2026 at 8:01 AM
Mar 4, 2026 at 3:41 AM
Apr 7, 2026 at 8:53 AM
May 13, 2026 at 8:01 AM
May 9, 2026 at 5:44 AM
May 13, 2026 at 8:17 AM
Apr 28, 2026 at 9:25 AM
May 6, 2026 at 6:47 AM
May 13, 2026 at 9:49 AM
May 13, 2026 at 8:10 AM
May 6, 2026 at 9:07 AM
May 13, 2026 at 9:21 AM
May 13, 2026 at 8:48 AM
May 13, 2026 at 8:58 AM
May 7, 2026 at 2:58 AM
May 13, 2026 at 9:09 AM
May 12, 2026 at 6:57 AM
May 13, 2026 at 9:43 AM
Apr 28, 2026 at 9:09 AM
May 13, 2026 at 9:30 AM
Apr 28, 2026 at 9:13 AM
May 13, 2026 at 9:16 AM
Apr 28, 2026 at 9:17 AM
May 13, 2026 at 9:05 AM
This website only serves as an information collection platform and does not provide related services. All content provided on the website comes from third-party public sources.Always seek the advice of a qualified professional in relation to any specific problem or issue. The information provided on this site is provided "as it is" without warranty of any kind, either express or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. The owners and operators of this site are not liable for any damages whatsoever arising out of or in connection with the use of this site or the information contained herein.